(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the Euronext session.

The three biggest winners today are ENVIPCO, MARTIFER, and SCATEC.

Financial Asset	Price	Change	Updated (EST)
ENVIPCO (ENVI.AS)	5.50	14.58%	2024-03-14 12:01:49
MARTIFER (MAR.LS)	1.79	12.97%	2024-03-14 12:23:42
SCATEC (SCATC.OL)	70.25	9.34%	2024-03-14 12:42:54
METABOLIC EXPLORER (METEX.PA)	0.18	8.95%	2024-03-14 13:20:21
FERMENTALG (FALG.PA)	0.60	8.45%	2024-03-14 13:03:28
PCI BIOTECH HOLD (PCIB.OL)	1.69	7.65%	2024-03-14 12:42:09
NEL (NEL.OL)	4.93	7.05%	2024-03-14 12:41:24
ODFJELL TECHNOLOGY (OTL.OL)	64.00	6.31%	2024-03-14 12:41:54
POXEL (POXEL.PA)	0.51	5.98%	2024-03-14 13:21:35
ID LOGISTICS GROUP (IDL.PA)	351.50	5.87%	2024-03-14 13:05:01

The three biggest losers today are POLIGHT, BASIC-FIT, and NR21.

Financial Asset	Price	Change	Updated (EST)
POLIGHT (PLT.OL)	4.40	-35.39%	2024-03-14 12:42:22
BASIC-FIT (BFIT.AS)	20.14	-14.52%	2024-03-14 12:00:51
NR21 (NR21.PA)	59.00	-13.24%	2024-03-14 13:20:49
MYHOTELMATCH (MHM.PA)	0.60	-13.04%	2024-03-14 13:20:28
MEMSCAP REGPT (MEMS.PA)	7.86	-9.86%	2024-03-14 13:20:14
BIOTALYS (BTLS.BR)	2.66	-9.52%	2024-03-14 12:05:20
PHARMING GROUP (PHARM.AS)	0.97	-9.07%	2024-03-14 12:03:26
MAAT PHARMA (MAAT.PA)	8.84	-7.92%	2024-03-14 13:06:10
AFFLUENT MEDICAL (AFME.PA)	1.89	-7.8%	2024-03-14 12:45:13
SOLSTAD OFFSHORE (SOFF.OL)	32.14	-7.06%	2024-03-14 12:43:17

Winners today

1. ENVIPCO (ENVI.AS)

14.58% Price Change

Envipco Holding N.V., together with its subsidiaries, designs, develops, manufactures, and sells or leases reverse vending machines (RVM) for the collection and processing of used beverage containers primarily in the Netherlands, North America, and Europe. The company provides technical support, RVM maintenance, and accounting services to the retail stores, bottlers, and distributors for containers redeemed through its machines. It also offers deposit, handling fees, scrap reconciliations, commodity brokerage, clearing house functions, and accounting services. In addition, the company provides materials handling services primarily in the northeastern part of the United States. Envipco Holding N.V. was incorporated in 1998 and is headquartered in Amersfoort, the Netherlands.

AEX-Index ended the session with ENVIPCO rising 14.58% to €5.50 on Thursday while AEX-Index fell 0.18% to €858.75.

Earnings Per Share

As for profitability, ENVIPCO has a trailing twelve months EPS of €-0.09.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.02%.

Volatility

ENVIPCO’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.23%, a positive 1.87%, and a positive 3.68%.

ENVIPCO’s highest amplitude of average volatility was 3.23% (last week), 4.55% (last month), and 3.68% (last quarter).

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 221.3% and 212.7%, respectively.

More news about ENVIPCO.

2. MARTIFER (MAR.LS)

12.97% Price Change

Martifer SGPS, S.A. operates in the metallic constructions and renewable energy development sectors worldwide. It operates through Metallic Constructions, Naval Industry, and Renewables segments. The Metallic Constructions segment engages in the construction activities involving metal mechanical construction, aluminum, and glass façades, as well as infrastructures for oil and gas. The Naval Industry segment involved in shipbuilding, as well as provides ship repair services. The Renewables segment engages in the development, licensing, building, and operating of renewable energy projects, including wind and solar power projects. The company was founded in 1990 and is headquartered in Oliveira de Frades, Portugal.

PSI ended the session with MARTIFER rising 12.97% to €1.79 on Thursday while PSI fell 0.9% to €6,055.53.

Earnings Per Share

As for profitability, MARTIFER has a trailing twelve months EPS of €0.13.

PE Ratio

MARTIFER has a trailing twelve months price to earnings ratio of 13.73. Meaning, the purchaser of the share is investing €13.73 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 53.03%.

Volatility

MARTIFER’s last week, last month’s, and last quarter’s current intraday variation average was 0.82%, 0.04%, and 2.86%.

MARTIFER’s highest amplitude of average volatility was 1.95% (last week), 2.27% (last month), and 2.86% (last quarter).

Yearly Top and Bottom Value

MARTIFER’s stock is valued at €1.79 at 21:40 EST, way above its 52-week high of €1.38.

Revenue Growth

Year-on-year quarterly revenue growth grew by 7.3%, now sitting on 211.48M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MARTIFER’s stock is considered to be oversold (<=20).

More news about MARTIFER.

3. SCATEC (SCATC.OL)

9.34% Price Change

Scatec ASA, together with its subsidiaries, provides renewable energy solutions worldwide. The company operates through Power Production; Services; and Development & Construction segments. It develops, builds, owns, and operates solar, wind, and hydro power plants and storage solutions. The company is also involved in the engineering, procurement, construction, operation, maintenance, and asset management of power plants. It has a total of 4.6 GW in operation and under construction. The company was formerly known as Scatec Solar ASA and changed its name to Scatec ASA in November 2020. Scatec ASA was incorporated in 2007 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with SCATEC jumping 9.34% to €70.25 on Thursday, after three successive sessions in a row of losses. Oslo Børs Benchmark Index_GI dropped 0.05% to €1,290.84, after two successive sessions in a row of gains, on what was a somewhat negative trend trading session today.

Earnings Per Share

As for profitability, SCATEC has a trailing twelve months EPS of kr-1.11.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.58%.

Yearly Top and Bottom Value

SCATEC’s stock is valued at kr70.25 at 21:40 EST, way under its 52-week high of kr85.50 and way higher than its 52-week low of kr52.50.

Growth Estimates Quarters

The company’s growth estimates for the present quarter is 113.7% and a drop 36.8% for the next.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on Apr 19, 2023, the estimated forward annual dividend rate is 1.94 and the estimated forward annual dividend yield is 2.84%.

More news about SCATEC.

4. METABOLIC EXPLORER (METEX.PA)

8.95% Price Change

METabolic EXplorer S.A., a biological chemistry company, engages in the development and industrialization of industrial fermentation processes as alternatives to petrochemical processes worldwide. The company also offers propanediol, butyric acid, butyric acid, glycolic acid, amino acid, and L-Valine. Its products are used in the formulation of cosmetics, textiles, polymer, animal nutrition, and health products or as intermediates for the synthesis of biomaterials. The company was incorporated in 1999 and is based in Saint-Beauzire, France.

CAC 40 ended the session with METABOLIC EXPLORER rising 8.95% to €0.18 on Thursday, after two sequential sessions in a row of losses. CAC 40 rose 0.29% to €8,161.42, after two consecutive sessions in a row of gains, on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, METABOLIC EXPLORER has a trailing twelve months EPS of €-0.98.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -42.82%.

More news about METABOLIC EXPLORER.

5. FERMENTALG (FALG.PA)

8.45% Price Change

Fermentalg SA develops, produces, and sells active ingredients extracted from microalgae for the food, health, nutrition, and environment sectors in France and internationally. It offers DHA ORIGINS, a plant-based DHA oil; KALVEA PLUS, a nutritious algal protein concentrate dedicated to aquafeed applications; Everzure, an extract of natural acid stable blue color; BLUE ORIGINS AOX, an antioxidant and anti-inflammatory activities; BLUE ORIGIN, a natural color; and environmental and clean air solutions that captures CO2 in industries. The company was incorporated in 2009 and is headquartered in Libourne, France.

CAC 40 ended the session with FERMENTALG jumping 8.45% to €0.60 on Thursday, following the last session’s upward trend. CAC 40 rose 0.29% to €8,161.42, after two consecutive sessions in a row of gains, on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, FERMENTALG has a trailing twelve months EPS of €-0.24.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.52%.

Volume

Today’s last reported volume for FERMENTALG is 261106 which is 67.59% below its average volume of 805677.

Volatility

FERMENTALG’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.64%, a negative 2.29%, and a positive 7.08%.

FERMENTALG’s highest amplitude of average volatility was 4.26% (last week), 6.27% (last month), and 7.08% (last quarter).

Yearly Top and Bottom Value

FERMENTALG’s stock is valued at €0.60 at 21:40 EST, way under its 52-week high of €1.52 and way above its 52-week low of €0.21.

More news about FERMENTALG.

6. PCI BIOTECH HOLD (PCIB.OL)

7.65% Price Change

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in pre-clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Olix Pharmaceuticals, Aposense, IMV Immunovaccine, MDimune, eTheRNA, and Immunicum. PCI Biotech Holding ASA was incorporated in 2007 and is based in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with PCI BIOTECH HOLD jumping 7.65% to €1.69 on Thursday, following the last session’s downward trend. Oslo Børs Benchmark Index_GI dropped 0.05% to €1,290.84, after two successive sessions in a row of gains, on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, PCI BIOTECH HOLD has a trailing twelve months EPS of kr-0.79.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -42.13%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, PCI BIOTECH HOLD’s stock is considered to be overbought (>=80).

Moving Average

PCI BIOTECH HOLD’s value is way under its 50-day moving average of kr2.03 and way below its 200-day moving average of kr1.98.

Revenue Growth

Year-on-year quarterly revenue growth grew by 8.4%, now sitting on 2.99M for the twelve trailing months.

More news about PCI BIOTECH HOLD.

7. NEL (NEL.OL)

7.05% Price Change

Nel ASA, a hydrogen company, provides various solutions to produce, store, and distribute hydrogen from renewable energy in Norway and internationally. The company operates in two segments, Nel Hydrogen Fueling and Nel Hydrogen Electrolyser. The Nel Hydrogen Fueling segment manufactures hydrogen fueling stations for fuel cell electric vehicles, such as cars, buses, trucks, and other on-road vehicles. The Nel Hydrogen Electrolyser segment supplies hydrogen production equipment based on alkaline and proton exchange membrane water electrolysis technology. It serves industries, energy, and gas companies. The company was formerly known as DiaGenic ASA and changed its name to Nel ASA in October 2014. Nel ASA was founded in 1927 and is headquartered in Oslo, Norway.

Oslo Børs Benchmark Index_GI ended the session with NEL rising 7.05% to €4.93 on Thursday while Oslo Børs Benchmark Index_GI dropped 0.05% to €1,290.84.

Earnings Per Share

As for profitability, NEL has a trailing twelve months EPS of kr-0.52.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -14.69%.

More news about NEL.

8. ODFJELL TECHNOLOGY (OTL.OL)

6.31% Price Change

Odfjell Technology Ltd., a technology and engineering company, provides well, drilling, and engineering services in Norway, Europe, Asia, the United Kingdom, and internationally. The company operates through three segments: Well Services; Operations; and Projects & Engineering. The Well Services segment provides casing and tubular running services, including automated and conventional; drilling tool and tubular rental services; and specialist well intervention products and services for exploration wells and for production. The Operations segment engages in the production of drilling and well completion on client's rigs. This segment is also involved in the slot recovery, plug and abandonment, work-overs, and maintenance activities; and provision of platform drilling services on both fixed production platforms and on floating production platforms with subsea blowout preventers along with the management and performance of the services on leased Jack-up rigs. The Projects & Engineering segment offers engineering and integrity services, including design and engineering to building supervision; and project management and operational support for units in operation, newbuild projects, and SPS/RS recertification projects and yard stays. The company was founded in 1973 and is headquartered in Aberdeen, the United Kingdom.

Oslo Børs Benchmark Index_GI ended the session with ODFJELL TECHNOLOGY rising 6.31% to €64.00 on Thursday, following the last session’s upward trend. Oslo Børs Benchmark Index_GI dropped 0.05% to €1,290.84, after two successive sessions in a row of gains, on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, ODFJELL TECHNOLOGY has a trailing twelve months EPS of kr7.92.

PE Ratio

ODFJELL TECHNOLOGY has a trailing twelve months price to earnings ratio of 8.08. Meaning, the purchaser of the share is investing kr8.08 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 37.1%.

Sales Growth

ODFJELL TECHNOLOGY’s sales growth is 10.8% for the ongoing quarter and 0.5% for the next.

Revenue Growth

Year-on-year quarterly revenue growth grew by 18.6%, now sitting on 5.02B for the twelve trailing months.

More news about ODFJELL TECHNOLOGY.

9. POXEL (POXEL.PA)

5.98% Price Change

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.

CAC 40 ended the session with POXEL rising 5.98% to €0.51 on Thursday while CAC 40 jumped 0.29% to €8,161.42.

Earnings Per Share

As for profitability, POXEL has a trailing twelve months EPS of €-1.08.

Revenue Growth

Year-on-year quarterly revenue growth grew by 1050.6%, now sitting on 1.55M for the twelve trailing months.

More news about POXEL.

10. ID LOGISTICS GROUP (IDL.PA)

5.87% Price Change

ID Logistics Group SA provides contract logistics services in France and internationally. It provides warehousing and value-added, transport and flow organization, and supply chain optimization services. The company also offers co-packing and site automation services. In addition, it provides turnkey project delivery and e-commerce solutions; and operates approximately 365 sites across 17 countries. The company serves customers in the FMCG, e-commerce, high-tech, cosmetics and fragrance, fashion, industrial, and retail sectors. The company was incorporated in 2001 and is headquartered in Orgon, France

CAC 40 ended the session with ID LOGISTICS GROUP jumping 5.87% to €351.50 on Thursday while CAC 40 jumped 0.29% to €8,161.42.

Earnings Per Share

As for profitability, ID LOGISTICS GROUP has a trailing twelve months EPS of €7.04.

PE Ratio

ID LOGISTICS GROUP has a trailing twelve months price to earnings ratio of 49.93. Meaning, the purchaser of the share is investing €49.93 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.31%.

Volatility

ID LOGISTICS GROUP’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.15%, a positive 0.08%, and a positive 0.99%.

ID LOGISTICS GROUP’s highest amplitude of average volatility was 0.53% (last week), 0.56% (last month), and 0.99% (last quarter).

More news about ID LOGISTICS GROUP.

Losers Today

1. POLIGHT (PLT.OL)

-35.39% Price Change

poLight ASA develops optical lens for consumer devices and industrial applications in Europe, Asia, and the United States. The company's lens replicates the lens of the human eye enabling the implementation of autofocus functions for various applications. Its product portfolio includes TLens, a tuneable optical lens for autofocus camera applications; Packaged TLens that facilitates integration of a TLens on a fixed-focus camera module; ASIC drivers, which control the supply of variable voltage to Tlens products and makes them to change focus; TLens Silver and TLens Silver Premium devices; and evaluation kits that allows to test and evaluate the optical and electrical performance of the TLens in new products and/or applications. it serves smartphones and wearables, barcode/industrial, augmented reality, medical endoscopy, webcams, and other markets. poLight ASA was founded in 2005 and is headquartered in Skoppum, Norway.

Oslo Børs Benchmark Index_GI ended the session with POLIGHT sliding 35.39% to €4.40 on Thursday, following the last session’s upward trend. Oslo Børs Benchmark Index_GI fell 0.05% to €1,290.84, after two consecutive sessions in a row of gains, on what was a somewhat bearish trend exchanging session today.

Earnings Per Share

As for profitability, POLIGHT has a trailing twelve months EPS of kr-1.2.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -38.27%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 42.1%, now sitting on 21.46M for the twelve trailing months.

Volatility

POLIGHT’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.59%, a negative 4.46%, and a positive 5.34%.

POLIGHT’s highest amplitude of average volatility was 2.04% (last week), 7.27% (last month), and 5.34% (last quarter).

Moving Average

POLIGHT’s value is way below its 50-day moving average of kr17.25 and way under its 200-day moving average of kr13.93.

Yearly Top and Bottom Value

POLIGHT’s stock is valued at kr4.40 at 21:40 EST, way under its 52-week low of kr5.95.

More news about POLIGHT.

2. BASIC-FIT (BFIT.AS)

-14.52% Price Change

Basic-Fit N.V., together with its subsidiaries, engages in the operation of fitness clubs. It operates 1200 clubs under Basic-Fit brand in Netherlands, Belgium, Luxembourg, Germany, France, and Spain. The company was founded in 1984 and is headquartered in Hoofddorp, the Netherlands.

AEX-Index ended the session with BASIC-FIT falling 14.52% to €20.14 on Thursday, after two sequential sessions in a row of gains. AEX-Index dropped 0.18% to €858.75, following the last session’s downward trend on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, BASIC-FIT has a trailing twelve months EPS of €0.27.

PE Ratio

BASIC-FIT has a trailing twelve months price to earnings ratio of 74.59. Meaning, the purchaser of the share is investing €74.59 for every euro of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.68%.

Volume

Today’s last reported volume for BASIC-FIT is 1740220 which is 1164.89% above its average volume of 137578.

More news about BASIC-FIT.

3. NR21 (NR21.PA)

-13.24% Price Change

NR21 Société Anonyme does not have significant operations. Previously, it was involved in design and distribution of underwear and indoor clothing for men, women, and children. The company is based in Paris, France.

CAC 40 ended the session with NR21 falling 13.24% to €59.00 on Thursday while CAC 40 rose 0.29% to €8,161.42.

Earnings Per Share

As for profitability, NR21 has a trailing twelve months EPS of €0.51.

PE Ratio

NR21 has a trailing twelve months price to earnings ratio of 115.69. Meaning, the purchaser of the share is investing €115.69 for every euro of annual earnings.

More news about NR21.

4. MYHOTELMATCH (MHM.PA)

-13.04% Price Change

MyHotelMatch S.A. engages in the development of an online hotel reservation platform based on Artificial Intelligence (AI). It operates as an online travel agency based on the principle of online dating. MyHotelMatch S.A. was incorporated in 2010 and is headquartered in Biot, France.

CAC 40 ended the session with MYHOTELMATCH sliding 13.04% to €0.60 on Thursday while CAC 40 rose 0.29% to €8,161.42.

Earnings Per Share

As for profitability, MYHOTELMATCH has a trailing twelve months EPS of €-1.1.

Volatility

MYHOTELMATCH’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.91%, a negative 1.02%, and a positive 3.89%.

MYHOTELMATCH’s highest amplitude of average volatility was 3.96% (last week), 4.04% (last month), and 3.89% (last quarter).

Yearly Top and Bottom Value

MYHOTELMATCH’s stock is valued at €0.60 at 21:40 EST, below its 52-week low of €0.64.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MYHOTELMATCH’s stock is considered to be overbought (>=80).

More news about MYHOTELMATCH.

5. MEMSCAP REGPT (MEMS.PA)

-9.86% Price Change

MEMSCAP, S.A. provides micro-electro-mechanical systems (MEMS) based solutions for aerospace and defense, optical communications, medical, and biomedical markets worldwide. The company offers pressure sensors, pressure transducers, and pressure switches for various applications, such as air data computers, cabin pressure, engine control, altimeters, barometers, cockpit instruments, and air data test sets. It also provides gold coated and titanium-based pressure transducers, plastic domes, line-sets, and related accessories. In addition, the company supplies optical MEMS chips for variable optical attenuators in optical telecommunication markets; and provides the multi-user MEMS processes. Further, it offers mounting brackets, snap holders, non-sterile and sterile domes, and monitoring line sets. MEMSCAP, S.A. was founded in 1997 and is based in Crolles, France.

CAC 40 ended the session with MEMSCAP REGPT falling 9.86% to €7.86 on Thursday, after three successive sessions in a row of losses. CAC 40 jumped 0.29% to €8,161.42, after two sequential sessions in a row of gains, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, MEMSCAP REGPT has a trailing twelve months EPS of €0.16.

PE Ratio

MEMSCAP REGPT has a trailing twelve months price to earnings ratio of 49.13. Meaning, the purchaser of the share is investing €49.13 for every euro of annual earnings.

Yearly Top and Bottom Value

MEMSCAP REGPT’s stock is valued at €7.86 at 21:40 EST, way under its 52-week high of €9.90 and way above its 52-week low of €2.19.

Volatility

MEMSCAP REGPT’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.77%, a positive 0.22%, and a positive 2.99%.

MEMSCAP REGPT’s highest amplitude of average volatility was 3.49% (last week), 2.52% (last month), and 2.99% (last quarter).

More news about MEMSCAP REGPT.

6. BIOTALYS (BTLS.BR)

-9.52% Price Change

Biotalys NV, an agricultural technology company, discovers and develops novel biological products for the protection of food and crops. It primarily develops biofungicides, bioinsecticides, and biobactericides. The company was formerly known as Agrosavfe NV. Biotalys NV was incorporated in 2013 and is headquartered in Gent, Belgium.

BEL 20 ended the session with BIOTALYS falling 9.52% to €2.66 on Thursday, after four successive sessions in a row of losses. BEL 20 dropped 0.98% to €3,691.85, following the last session’s downward trend on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, BIOTALYS has a trailing twelve months EPS of €-0.76.

More news about BIOTALYS.

7. PHARMING GROUP (PHARM.AS)

-9.07% Price Change

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

AEX-Index ended the session with PHARMING GROUP dropping 9.07% to €0.97 on Thursday, following the last session’s downward trend. AEX-Index slid 0.18% to €858.75, following the last session’s downward trend on what was a somewhat down trend trading session today.

Earnings Per Share

As for profitability, PHARMING GROUP has a trailing twelve months EPS of €-0.03.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -10.75%.

Volatility

PHARMING GROUP’s last week, last month’s, and last quarter’s current intraday variation average was 0.43%, 0.07%, and 1.55%.

PHARMING GROUP’s highest amplitude of average volatility was 0.75% (last week), 1.24% (last month), and 1.55% (last quarter).

More news about PHARMING GROUP.

8. MAAT PHARMA (MAAT.PA)

-7.92% Price Change

MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.

CAC 40 ended the session with MAAT PHARMA dropping 7.92% to €8.84 on Thursday, after three successive sessions in a row of gains. CAC 40 rose 0.29% to €8,161.42, after two consecutive sessions in a row of gains, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, MAAT PHARMA has a trailing twelve months EPS of €-1.4.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -46.11%.

Moving Average

MAAT PHARMA’s value is way above its 50-day moving average of €6.11 and way above its 200-day moving average of €7.83.

Volume

Today’s last reported volume for MAAT PHARMA is 1575 which is 8.32% above its average volume of 1454.

Volatility

MAAT PHARMA’s last week, last month’s, and last quarter’s current intraday variation average was 2.56%, 1.94%, and 3.29%.

MAAT PHARMA’s highest amplitude of average volatility was 5.61% (last week), 4.68% (last month), and 3.29% (last quarter).

Yearly Top and Bottom Value

MAAT PHARMA’s stock is valued at €8.84 at 21:40 EST, way under its 52-week high of €11.10 and way above its 52-week low of €4.50.

More news about MAAT PHARMA.

9. AFFLUENT MEDICAL (AFME.PA)

-7.8% Price Change

Affluent Medical SA develops minimally invasive medical devices for the treatment of heart and vascular diseases in France. It develops Kardiozis technology for the treatment of abdominal aortic aneurysm; Kalios and Epygon implants to treat mitral insufficiency; and Artus implant, an implantable electro-mechanical artificial sphincter for the treatment of severe urinary incontinence in women and men. The company was founded in 2011 and is based in Aix-en-Provence, France.

CAC 40 ended the session with AFFLUENT MEDICAL sliding 7.8% to €1.89 on Thursday while CAC 40 rose 0.29% to €8,161.42.

Earnings Per Share

As for profitability, AFFLUENT MEDICAL has a trailing twelve months EPS of €-0.65.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -40.37%.

More news about AFFLUENT MEDICAL.

10. SOLSTAD OFFSHORE (SOFF.OL)

-7.06% Price Change

Solstad Offshore ASA operates offshore service vessels and maritime services to offshore energy industry. It owns and operates platform supply vessel, anchor handling tug support vessel, and construction service vessels. The company offers subsea construction and renewable energy services, such as geotechnical work, walk to work services, grouting, SURF operations, cable laying and repair, trenching and burial, ROV support, installation of subsea equipment, survey work, IMR operations, node seismic operations, and diving and topside maintenance work. It operates a fleet of 27 construction service vessels, 20 anchor handling tug support vessels, and 39 platform supply vessels. The company was founded in 1964 and is headquartered in Skudeneshavn, Norway.

Oslo Børs Benchmark Index_GI ended the session with SOLSTAD OFFSHORE dropping 7.06% to €32.14 on Thursday while Oslo Børs Benchmark Index_GI slid 0.05% to €1,290.84.

Earnings Per Share

As for profitability, SOLSTAD OFFSHORE has a trailing twelve months EPS of kr0.59.

PE Ratio

SOLSTAD OFFSHORE has a trailing twelve months price to earnings ratio of 54.47. Meaning, the purchaser of the share is investing kr54.47 for every norwegian krone of annual earnings.

Return on Equity

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.32%.

More news about SOLSTAD OFFSHORE.

Stay up to date with our winners and losers daily report